Home Daily Intelligence Tracker
    • Plans Blog Contact
    HUTCHMED DRC logo
    HCM

    HUTCHMED DRC

    MaveScore 7 Low model confidence
    Last Price US$10.99 As of Jul 09, 2026
    Market Cap US$10.0b Company size context
    7D Performance 1.85% Past 7 days
    1Y Performance -27.70% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Updating

    Refreshing

    Market price date

    Jul 09, 2026

    1 day old

    Coverage

    10/16

    6 missing model inputs

    Data quality

    Review

    Partial or delayed snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 7 Low confidence

    Stored data quality

    Freshness and coverage checks

    Stored company inputs are available, but some dates or model fields are older or incomplete.

    10/16 Partial or delayed snapshot

    Quality

    Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

    7/35 Weak

    Financial Strength

    Financial strength needs live profitability and cash-flow fields.

    0/25 Needs Data

    Valuation Support

    Valuation needs price plus per-share earnings, cash-flow, or book-value inputs.

    0/15 Needs Data

    Momentum

    Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    0/15 Weak

    Shareholder Alignment

    Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

    0/10 Weak

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
    • Financial strength needs live profitability and cash-flow fields.
    • Valuation needs price plus per-share earnings, cash-flow, or book-value inputs.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include return on equity, net margin, gross margin, free cash flow per share, book value per share, earnings per share.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Deep..lue Prediction Screener Map

    HUTCHMED DRC Overview

    Industry: Drug Manufacturers Specialty & Generic

    Sector: Healthcare

    HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma Read More

    HUTCHMED DRC is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    HUTCHMED DRC

    Score

    Reported Results

    No latest earnings report cached yet

    Run the EDGAR earnings refresh to load the latest company-filed earnings release, 10-Q, 10-K, or transcript exhibit for this ticker.

    Recent News



    News Image
    Should You Buy HUTCHMED (China) Ltd (HCM) Stock Wednesday Morning?
    3 hours ago
    News Image
    HCM Acquisition Corp (NASDAQ:HCMA) Sees Large Increase in Short Interest
    5 hours ago
    News Image
    HUTCHMED (LON:HCM) Stock Passes Below 200 Day Moving Average of $263.01
    5 hours ago

    Earnings Per Share

    Score 1.00/5
    HUTCHMED DRC earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes ZTS IQV A
    In Drug Manufacturers Specialty & Generic industry , ZTS , AMPH , PBH are companies with high ratings.

    Return on Equity

    Score 1.75/5
    HUTCHMED DRC exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include ZTS IQV A

    0% 10.0% 20.0% 30.0% 40.0%

    ROE

    Company 0%

    Sector Median 0%

    0% 10.0% 20.0% 30.0% 40.0%

    ROE

    Company 0%

    Sector Median 0%

    0% 10.0% 20.0% 30.0% 40.0%

    ROE

    Company 0%

    Sector Median 0%

    0% 10.0% 20.0% 30.0% 40.0%

    ROE

    Company 0%

    Sector Median 0%

    In Drug Manufacturers Specialty & Generic industry , ZTS , AMPH , PBH are companies with high ratings.

    0% 10.0% 20.0% 30.0% 40.0%

    ROE

    Company 0%

    Sector Median 0%

    0% 10.0% 20.0% 30.0% 40.0%

    ROE

    Company 0%

    Sector Median 0%

    0% 10.0% 20.0% 30.0% 40.0%

    ROE

    Company 0%

    Sector Median 0%

    0% 10.0% 20.0% 30.0% 40.0%

    ROE

    Company 0%

    Sector Median 0%

    Net Margin

    Score 1.80/5
    HUTCHMED DRC olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include ZTS IQV A

    0% 10.0% 20.0% 30.0% 40.0%

    Net Margin

    Company 0%

    Sector Median 0%

    0% 10.0% 20.0% 30.0% 40.0%

    Net Margin

    Company 0%

    Sector Median 0%

    0% 10.0% 20.0% 30.0% 40.0%

    Net Margin

    Company 0%

    Sector Median 0%

    0% 10.0% 20.0% 30.0% 40.0%

    Net Margin

    Company 0%

    Sector Median 0%

    In Drug Manufacturers Specialty & Generic industry , ZTS , AMPH , PBH are companies with high ratings.

    0% 10.0% 20.0% 30.0% 40.0%

    Net Margin

    Company 0%

    Sector Median 0%

    0% 10.0% 20.0% 30.0% 40.0%

    Net Margin

    Company 0%

    Sector Median 0%

    0% 10.0% 20.0% 30.0% 40.0%

    Net Margin

    Company 0%

    Sector Median 0%

    0% 10.0% 20.0% 30.0% 40.0%

    Net Margin

    Company 0%

    Sector Median 0%

    Share Buyback

    In Drug Manufacturers Specialty & Generic industry , ZTS , AMPH , PBH are companies with high ratings.

    Leverage

    Score 2.54/5
    HUTCHMED DRC attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as ZTS IQV A , also exhibit high scores.

    0    10.0    20.0    30.0    40.0   

    Leverage

    Company 0

    Sector Median 0

    0    10.0    20.0    30.0    40.0   

    Leverage

    Company 0

    Sector Median 0

    0    10.0    20.0    30.0    40.0   

    Leverage

    Company 0

    Sector Median 0

    0    10.0    20.0    30.0    40.0   

    Leverage

    Company 0

    Sector Median 0

    In Drug Manufacturers Specialty & Generic industry , ZTS , AMPH , PBH are companies with high ratings.

    0    10.0    20.0    30.0    40.0   

    Leverage

    Company 0

    Sector Median 0

    0    10.0    20.0    30.0    40.0   

    Leverage

    Company 0

    Sector Median 0

    0    10.0    20.0    30.0    40.0   

    Leverage

    Company 0

    Sector Median 0

    0    10.0    20.0    30.0    40.0   

    Leverage

    Company 0

    Sector Median 0

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Loading SEC financial statements...

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    HUTCHMED DRC logo

    HUTCHMED DRC

    US$10.99

    US$10.0b

    1.85%

    -27.70%